Predicting Lung Cancer Survival: A New Tool for Patients

ByHolly Zink
Predicting Lung Cancer Survival: A New Tool for Patients

Lung cancer is a tough opponent, causing a lot of harm worldwide. In Morocco, it’s a big concern, making up most non-small cell lung cancers and a chunk of small cell lung cancers. Scientists have created a new tool, a special chart, to predict how long someone might live with lung cancer.

Mesothelioma is a rare and aggressive cancer caused by asbestos exposure. It shares some commonalities with lung cancer in terms of its impact and treatment challenges. While they have their differences, both diseases affect the lungs and can have similar treatment approaches.

Lung Cancer and Mesothelioma

Top of Form

Treating early-stage lung cancer often involves a mix of treatments. These include chemotherapy, radiation, and sometimes surgery. But not all patients respond the same way to these treatments. Things like age, how urgent the medical situation is, how well the patient is, and the type of treatment they get can affect how long they survive with lung cancer.

To make better predictions about how long patients might live with lung cancer, a group of researchers in Morocco studied 1,104 patients. They looked at different factors like age, urgency of the situation when diagnosed, how well the patient was, and if they had surgery or radiation. They put all this info into a special chart called a nomogram to predict how long someone might live with lung cancer.

What Did They Find?

They discovered that a few things really matter in how long someone might live with lung cancer. Age, how urgent the situation was when diagnosed, how well the patient was, and whether they had surgery or radiation are key factors. These factors give doctors a better idea of how long someone might live with lung cancer.

The predictive tool developed for lung cancer survival might also offer insights or adaptations applicable to mesothelioma patients. Understanding the factors influencing survival in lung cancer could potentially shed light on predictive elements for mesothelioma patients.

This could help in better prognostic assessments and tailored treatment strategies for mesothelioma. Further research exploring the applicability of this tool in the context of mesothelioma could be a valuable next step in improving outcomes for individuals affected by this disease.

What Does This Mean for Patients?

This special chart could help doctors and patients make better decisions about treatment. By understanding how different things affect survival, doctors can plan treatments that might work better for each patient. It’s like having a roadmap to guide doctors in making treatment choices.

This study has some limits. They need more research across Africa to be sure these factors affect everyone in the same way. Also, they couldn’t include some newer tests for genes or details about treatments in the study. These could make the predictions even more accurate.

This new tool could be a game-changer for lung cancer patients. By predicting how long someone might live with lung cancer, doctors can plan better, help patients make informed choices, and design studies that compare treatments more effectively.

Source:

Tafenzi, Hassan Abdelilah, Farah Choulli, Ganiou Adjade, Anas Baladi, Leila Afani, Mohammed El Fadli, Ismail Essaadi, and Rhizlane Belbaraka. “Development of a Well-Defined Tool to Predict the Overall Survival in Lung Cancer Patients: An African Based Cohort.” BMC Cancer 23, no. 1 (October 20, 2023): 1016. https://doi.org/10.1186/s12885-023-11355-7.

 

Similar Posts

  • |

    New Prognostic Factor in Peritoneal Mesothelioma

    ByAlex Strauss

    Malignant peritoneal mesothelioma is a rare form of mesothelioma that attacks the membrane that lines the abdomen and surrounds internal organs. The outlook for this rare malignancy, which affects fewer than 500 Americans annually, has been improved by the treatment combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The combination has produced 5-year overall survival rates ranging from 29% to 63%. But not all peritoneal mesothelioma patients are good candidates for CRS/HIPEC. The challenge, for clinicians, is identifying which patients are likely to benefit from the procedure (or even be cured) and which are not. In an effort to help answer that question, French researchers recently tested the prognostic value of the glucose transporter protein GLUT1 as well as…

  • |

    Study Lists Factors That Impact Mesothelioma Prognosis

    ByAlex Strauss

    Predicting survival in mesothelioma patients does not have to be complicated. A new Parisian study suggests that simple-to-measure factors such as patient age and the histological subtype of the mesothelioma can be highly accurate prognostic indicators. The study followed 170 patients diagnosed with malignant pleural mesothelioma between 2000 and 2010 at Saint Antoine Hospital in Paris. Patients in the study were all treated non-surgically. For each patient, a list of parameters was recorded including age, gender, tobacco use, asbestos exposure, type and duration of symptoms, BMI, C-reactive protein levels and white blood cell and platelet counts.  Inflammation of the pleura (pachypleuritis) was also noted, along with the type of diagnostic surgical procedure, histological subtype, the way in which pleurodesis was performed (for…

  • |

    Predicting Mesothelioma Outcomes with Blood Tests

    ByAlex Strauss

    Two separate teams of Japanese researchers are delving into the possibilities of blood serum indicators that could help predict outcomes in patients with malignant pleural mesothelioma. Mesothelioma is a rare but aggressive cancer caused by exposure to asbestos. Pleural mesothelioma, a cancer that starts on the lining around the lungs, is the most common form of the disease. It occurs most often in people who have inadvertently inhaled asbestos dust. Mesothelioma is highly resistant to conventional treatments. It is also difficult to predict which patients are likely to do well with standard therapies and which are not, which is referred to as prognosis. But researchers worldwide are continually searching for new ways to diagnose and predict the prognosis of patients with…

  • |

    Drop in Lung Volume Predicts Poor Mesothelioma Outcome

    ByAlex Strauss

    Decreases in lung volume may be an indicator of treatment response for patients with mesothelioma. Researchers in the U.S. and Australia reached that conclusion after studying the cases of 61 patients with malignant pleural mesothelioma and 216 CT scans taken of them during the course of their standard chemotherapy treatment. Lung volume is a measurement of the amount of air the lung processes (inhales, exhales and holds on to) during the course of a normal breath. People with malignant pleural mesothelioma, a cancer that starts on the lining around the lungs, typically experience a drop in lung volume as the pleural tumor grows and constricts or even invades one of their lungs. The new study measured changes in each mesothelioma patient’s…

  • |

    New Prognostic Tools Could Improve Mesothelioma Treatment

    ByAlex Strauss

    A pair of cancer researchers from Rome say treatment for malignant pleural mesothelioma could be improved if more clinicians considered the newest prognostic tools in their treatment planning. Pleural mesothelioma is a malignancy of the membranes that encase the lungs. It is caused by exposure to the mineral asbestos and is highly resistant to conventional cancer therapies. Many mesothelioma patients do not survive longer than 12 months from the onset of their symptoms. But Tommaso Mineo, MD, and Vincenzo Ambrogi, PhD, of the Department of Experimental Medicine and Surgery at Policlinico Tor Vergata University say newly discovered biomarkers and other tumor factors could lead to more tailored treatment and, potentially, better outcomes. “Therapy is currently guided by gross tumor characteristics and patient…

  • |

    For Some Patients Chemo Cuts Mesothelioma Survival

    ByAlex Strauss

    Asbestos disease researchers in Australia say chemotherapy at the end of life may be doing some mesothelioma patients more harm than good. The team from the Asbestos Diseases Research Institute in Rhodes, Australia analyzed the cases of 147 malignant pleural mesothelioma patients who had received compensation from the government’s Dust Diseases Board. The focus of the study was to determine the association between a variety of factors such as age, gender, geographic location, disease stage, histological subtype, length of first-line chemotherapy, and the use of chemotherapy in the last month of their lives. Among the mesothelioma patients studied, most (77%) received more than one treatment modality while 56% received only one. Chemotherapy, which continues to be the most popular first-line treatment…